Angiogenic growth factors and their receptors in first-trimester human decidua of pregnancies further complicated by preeclampsia or fetal growth restriction

Reproductive Sciences

Volumn 15, Issue 7, 2008, Pages 720-726

  Plaisier, M ^a,b   Streefland, E ^c   Koolwijk, P ^d   Van Hinsbergh, V W M ^d   Helmerhorst, F M ^a   Erwich, J J H M ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenic factors; Decidua; Fetal growth restriction; First trimester; Preeclampsia

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DECIDUA; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN TISSUE; INTRAUTERINE GROWTH RETARDATION; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANGIOGENESIS INDUCING AGENTS; DECIDUA; FEMALE; FETAL GROWTH RETARDATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; RECEPTOR, TIE-2; RECEPTORS, GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 52449119023     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719108317300     Document Type: Article

References (42)

1. Ahmed A., Perkins J. Angiogenesis and intrauterine growth retardation. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 ; 14: 981-998.
2. Ong S., Lash G., Baker PN Angiogenesis and placental growth in normal and compromised pregnancies. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 ; 14: 969-980.
3. Torry DS, Hinrichs M., Torry RJ Determinants of placental vascularity. Am J Reprod Immunol. 2004 ; 51: 257-268.
4. Luttun A., Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered ? J Clin Invest. 2003 ; 111: 600-602.
5. Maynard SE, Min J., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sflt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 ; 111: 649-658.
6. Burton GJ, Jauniaux E., Watson AL Maternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: the Boyd collection revisited. Am J Obstet Gynecol. 1999 ; 181: 718-724.
7. Pijnenborg R., Bland JM, Robertson WB, Brosens I. Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. Placenta. 1983 ; 4: 397-413.
8. Zhou Y., McMaster M., Woo K., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002 ; 160: 1405-1423.
9. Geva E., Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A., Jaffe RB Human placental vascular development: vasculogenic and angiogenic transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1 and angiopoietin-2. J Clin Endocrinol Metab. 2002 ; 87: 4213-4224.
10. Das SK, Chakraborty I., Wang J., Dey SK, Hoffman LH Expression of vascular endothelial growth factor (VEGF) and VEGF-receptor messenger ribonucleic acids in the peri-implantation rabbit uterus. Biol Reprod. 1997 ; 56: 1390-1399.
11. Plaisier M., Rodrigues S., Willems F., et al. Different degree of vascularisation and its relation to the expression of VEGF, PlGF, angiopoietins and their receptors in 1st trimester decidua. Fertil Steril. 2007 ; 88: 176-187.
12. Chung J., Song Y., Wang Y., Magness RR, Zheng J. Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2004 ; 89: 2484-2490.
13. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001 ; 7: 575-583.
14. Luttun A., Tjwa M., Moons L., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002 ; 8: 831-840.
15. Sherer DM, Abulafia O. Angiogenesis during implantation, and placental and early embryonic development. Placenta. 2001 ; 22: 1-13.
16. Geva E., Jaffe RB Role of angiopoietins in reproductive tract angiogenesis. Obstet Gynecol Surv. 2000 ; 55: 511-519.
17. Maisonpierre PC, Suri C., Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997 ; 277: 55-60.
18. Asahara T., Chen D., Takahashi T., et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998 ; 83: 233-240.
19. Li XF, Charnock-Jones DS, Zhang E., Hiby S., Malik S., Day K. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J Clin Endocrinol Metab. 2001 ; 86: 1823-1834.
20. Roberts JM, Cooper DW Pathogenesis and genetics of preeclampsia. Lancet. 2001 ; 357: 53-56.
21. Taylor RN, Grimwood J., Taylor RS, McMaster MT, Fisher SJ, North RA Longitudinal serum concentrations of PlGF: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003 ; 188: 177-182.
22. Kloosterman GJ Over intra-uteriene groei en de intra-uteriene groeicurve. [Intrauterine growth and intrauterine growth curves]. Ned Tijdschr Verloskd Gynaecol. 1969 ; 69: 349-365.
23. Clark DE, Smith SK, He Y., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod. 1998 ; 59: 1540-1548.
24. Tjoa ML, Levine RJ, Karumanchi SA Angiogenic factors in preeclampsia. Front Biosci. 2007 ; 112: 2395-2402.
25. Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in pre-eclampsia. Circ Res. 2004 ; 95: 884-891.
26. Hayman R., Brockelsby J., Kenny L., Baker P. Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. J Soc Gynecol Investig. 1999 ; 6: 3-10.
27. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003 ; 278: 12605-12608.
28. Ranheim T., Staff AC, Henriksen T. VEGF mRNA is unaltered in decidual and placental tissues in preeclampsia at delivery. Acta Obstet Gynecol Scand. 2001 ; 80: 93-98.
29. Sgambati E., Marini M., Zappoli, et al. VEGF expression I the placenta from pregnancies complicated by hypertensive disorders. BJOG. 2004 ; 111: 564-570.
30. Lam C., Lim KH, Karumanchi SA Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005 ; 46: 1077-1085.
31. Zhang EG, Smith SK, Baker PN, Charnock-Jones DS The regulation and localization of angiopoietin-1, -2, and their receptor Tie2 in normal and pathologic human placentae. Mol Med. 2001 ; 7: 624-635.
32. Levine RJ, Maynard SE, Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004 ; 350: 672-683.
33. Bosio PM, Wheeler T., Anthony F., Conroy R., O'Herlihy C., McKenna P. Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am J Obstet Gynecol. 2001 ; 184: 146-152.
34. Tsatsaris V., Goffin F., Munaut C., et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathological consequences. J Clin Endocrinol Metab. 2003 ; 88: 5555-5563.
35. Burton GJ On 'oxygen and placental villous development: origins of fetal hypoxia'. Placenta. 1997 ; 18: 625-626.
36. Kingdom JCP, Kaufmann P. Oxygen and placental villous development: origins of fetal hypoxia. Placenta. 1997 ; 18 ; 613-621.
37. Regnault TRH, de Vrijer B., Galan HL, et al. The relationship between transplacental O2 diffusion and placental expression of PlGF, VEGF, and their receptors in a placental insufficiency model of fetal growth restriction. J Physiol. 2003 ; 550: 641-656.
38. Lyall F. Placental expression of VEGF in placentae of preeclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. Placenta. 1997 ; 18: 269-276.
39. Khaliq A., Dunk C., Jiang J., et al. Hypoxia downregulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab Invest. 1999 ; 79: 151-170.
40. Erickson Hagen AS, Orbus RJ, Wilkening RB, Regnault TRH, Anthony RV Placental expression of angiopoietin-1, angiopoietin-2 and Tie-2 during placental development in an ovine model of placental insufficiency-fetal growth restriction. Pediatr Res. 2005 ; 58: 1228-1232.
41. Sharkey AM, Day K., McPherson A., et al. Vascular endothelial growth factor expression in humane endometrium is regulated by hypoxia. J Clin Endocrinol Metab. 2000 ; 85: 402-409.
42. Cooper JC, Sharkey AM, Charnock-Jones D., Palmer CR, Smith SK VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. BJOG. 1996 ; 103: 1191-1996.